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Abstract 
 
Introduction: Recently two algorithms have become available to estimate the 10-year 
probability of fracture in patients suspected to have osteoporosis on the basis of 
clinical risk factors (CRF); the FRAX algorithm and QFractureScores algorithm 
(QFracture). The aim of this study was to compare the performance of these 
algorithms in a study of fracture patients and controls recruited from six centres in the 
UK and Ireland.  
Methods: A total of 246 postmenopausal women aged 50-85 years who had recently 
suffered a low trauma fracture were enrolled and their characteristics were compared 
with 338 female controls who had never suffered a fracture. Measurements of femoral 
bone mineral density (BMD) were performed by dual energy X-ray absorptiometry 
(DXA) and fracture risk was calculated using the FRAX and QFracture algorithms. 
Results: The FRAX algorithm yielded higher calculated scores for fracture risk than 
the QFracture algorithm. Accordingly, the risk of major fracture in the overall study 
group was 9.5% for QFracture compared with 15.2% for FRAX. For hip fracture risk 
the values were 2.9% and 4.7% respectively. The correlation between FRAX and 
QFracture was R=0.803 for major fracture and R=0.857 for hip fracture (p≤0.0001). 
Both algorithms yielded high specificity but poor sensitivity for prediction of 
osteoporosis. 
Conclusions: We conclude that the FRAX and QFracture algorithms yield similar 
results in the estimation of fracture risk. Both of these tools could be of value in 
primary care to identify patients in the community at risk of osteoporosis and fragility 
fractures for further investigation and therapeutic intervention.  
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Introduction 
 
Osteoporosis is a common condition characterised by low bone mass and an increased 
risk of low trauma fracture [1, 2]. Currently, the diagnosis of osteoporosis is based on 
bone densitometry and the disease is defined to exist when BMD values at the spine 
or hip fall 2.5 standard deviations or more below normal values in young healthy 
individuals. Although BMD values can be measured conveniently and non-invasively 
by dual energy X-ray absorptiometry (DXA), not all physicians have access to this 
test. In addition many patients who suffer fragility fractures do not have osteoporosis 
as defined by DXA [3], demonstrating that complementary approaches are required to 
develop new techniques to better identify patients at risk of fragility fractures. 
Reflecting this fact, a recent report by the World Health Organisation (WHO) has 
recommended that research be conducted into the use of alternative technologies to 
DXA [4].  
 
Osteoporosis is a multifactorial disease and many clinical risk factors (CRF) for 
susceptibility to the disease have been identified [5-11], some of which increase the 
risk of fracture independently of BMD [12]. This has led to the development of 
algorithms to assess fracture risk on the basis of CRF in the absence of BMD 
measurements. The first of these to be developed was the FRAX algorithm which 
used data from nine prospective population-based cohorts (190,000 patient years) 
from Europe, North America, Australia and Japan [13] and validated the performance 
in eleven independent population-based cohorts (1.2 million person-years) [14]. The 
FRAX algorithm is country specific as fracture rates vary considerably in different 
countries [15].  
 
A limitation of the FRAX tool is that for several of the CRF, such as corticosteroid 
use, alcohol and smoking, no account is taken of the magnitude of exposure and also 
that no information is collected in falls – an important risk factor for fragility fracture 
[16, 17]. In order to address this and other issues, the QFractureScores algorithm 
(QFracture) was developed to estimate fracture risk based on CRF alone. [18]. The 
QFracture tool was developed using data from a prospective cohort study of 1, 
183,663 females and 1,174,232 males in the UK (15.9 million person-years) and the 
4 
 
validation cohort was composed of 642,153 females and 633,764 males [18].  
QFracture uses many of the CRF included in FRAX in addition to other variables that 
influence fracture risk (Table 1). Unlike FRAX the QFracture algorithm does not 
incorporate BMD or previous fractures but does include more detailed information on 
dose response for variables like alcohol intake and smoking habit. The age-range has 
also been extended in the QFracture algorithm (30-85 years) to allow for assessment 
of younger patients [18].  
 
The aim of this study was to compare the performance of the FRAX and QFracture 
algorithms in identifying patients who suffered fractures in a case-control study of 
postmenopausal women recruited from the UK and Ireland. 
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Table 1. Clinical Risk Factors evaluated by the FRAX and QFracture algorithms 
   
Clinical Risk Factor FRAX QFracture 
Age X X 
Sex X X 
Weight X X 
Height X X 
Previous fracture X  
Parental hip 
fracture/osteoporosis 
X X 
Smoking X X 
Glucocorticoids* X X 
Rheumatoid arthritis X X 
Secondary osteoporosis** X  
Alcohol Intake X X 
Femoral neck BMD X  
Asthma  X 
Heart attack/Stroke  X 
Falls  X 
Chronic liver disease  X 
Tricyclic antidepressants  X 
Type 2 diabetes  X 
HRT  X 
Endocrine problem  X 
Malabsorption  X 
Menopausal symptoms  X 
     
 * In QFracture the use of “steroids” is recorded rather than glucocorticoids.   
** In QFracture secondary causes of osteoporosis are not recorded as a single entity, but are recorded 
separately as shown above.   
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Materials and Methods 
 
The cases and controls were recruited as part of a multi-centre study in Ireland and the 
UK. Subject recruitment by geographical region was as follows; England n=237, 
Ireland n=88, Scotland n=195 and Wales n=64. The study received ethical approval 
(MREC 07/Q1704/1) and all subjects gave written informed consent to participating. 
All participants were Caucasian women aged between 50 and 85 years who were at 
least 5 years post-menopausal. To fully assess the performance of both tools in the 
identification of patients at risk of future fracture, participants included subjects who 
had recently suffered a fracture (cases) in combination with individuals who had 
never suffered a fracture (controls). All of the fracture cases had suffered a low-
trauma fracture at the hip, spine, humerus, pelvis or wrist, after the age of 45 years 
whereas the controls were subjects who had never sustained a fracture during 
adulthood (age >18 years). We excluded subjects who were receiving treatment for 
osteoporosis, those on corticosteroids and those with secondary cause of osteoporosis 
such as malabsorption, chronic liver disease, renal failure and malignant disease.  
 
The FRAX scores were calculated manually from the FRAX website 
www.shef.ac.uk/FRAX with double data-entry in 10% of subjects. The UK version of 
FRAX was used for all subjects as an Irish version of FRAX is not currently 
available. The 10-year probabilities of major osteoporotic and hip fracture with and 
without BMD were recorded for FRAX. Values for QFracture were assessed using the 
published algorithm (Web version 1) as implemented at www.qfracture.org and the 
10-year probabilities of major osteoporotic and hip fracture were recorded.   
 
Statistical analysis was performed using SPSS software V17 (Microsoft, California, 
USA). Descriptive statistics are presented as mean values and standard deviations 
(SDs). Variables were tested for normality using the Kolmogorov-Smirnov test. 
Depending on the normality of the distribution, Pearsons or Spearmans correlation 
coefficients were calculated to examine the relationship between variables. The 
Students t-test or the Mann-Whitney test (MWU) was used, as appropriate, for 
comparisons of two groups. Receiver Operating Curve (ROC) analysis was performed 
to calculate Sensitivity, Specificity and Area Under the Curve (AUC) values. 
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Results 
 
Characteristics of the Study Sample 
Characteristics of the study population are summarised in Table 2. There was a 
significant difference in age (p≤0.01), history of falls (p≤0.0001) and femoral 
BMD/T-score (p≤0.0001) between the fracture cases and controls. The most common 
fracture type was wrist fracture (n=173; 70%), followed by fractures of the humerus 
(n=30; 12%), fractures of the hip (n=22; 9%), and fractures of the spine (n=21; 9%).  
A history of falls was recorded in 39% of the total sample (n=227) and 32% of 
subjects had a family history of osteoporosis (n=188). A diagnosis of osteoporosis 
was confirmed in 15% of the sample (n=87) and 57% were identified as osteopenic 
(n=333). BMI ranged from 15.8-49.3 kg/m
2
 with 2% underweight (n=10), 32% 
normal weight (n=188), 40% overweight (n=234) and 26% categorised as being obese 
(n=152). Current smokers comprised 15% of the sample (n=87) and 33% were ex-
smokers (n=190) with 9% of subjects (n=50) reporting an alcohol intake of ≥14 U/wk. 
 
Table 2 Characteristics of the Study Population 
 
Fractures 
(n=246) 
Controls 
(n=338) 
p-value 
Age (y) 68 ± 8 66 ± 7 0.002 
Height (m) 1.59 ± 0.06 1.60 ± 0.06 0.051 
Weight (kg) 69 ± 13 70 ± 13 0.296 
BMI (kg/m
2
) 27.1 ± 5.0 27.3 ± 5.0 0.683 
Femoral BMD (g/cm
2
) 0.670 ± 0.109 0.739 ±  0.136 0.0001 
Femoral BMD (T-score) -1.7 ± 0.9 -1.2 ± 1.1 0.0001 
Relative with Fracture (n) 75 (30) 113  (33) 0.452 
History of Falls (n) 158 (64) 69 (20)  0.0001 
Current Smoker (n) 38 (15) 49 (15)  0.992 
Alcohol ≥14 U/wk (n) 23 (9) 27 (8)  0.562 
    
Values are mean ± SD or numbers (%) 
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Absolute Fracture Risk 
The estimated absolute fracture risks are summarised in Table 3. The risks generated 
by the QFracture algorithm were consistently lower than those calculated by the 
FRAX algorithm (excluding a BMD measurement). In the total study sample the 
mean major fracture risk for QFracture was 9.5% (range 1.7 - 37.0%) vs. 15.2% (3.4 – 
49.0%) for FRAX. Similarly for hip fracture risk the values were 2.9% (range 0.2 - 
29.6%) and 4.7% (0.2 – 36.0%) respectively. Overall however, there was a significant 
correlation between the risks calculated by QFractureScores and FRAX as 
demonstrated in Figure 1. The correlation for major fracture was r=0.803 and for hip 
fracture was r=0.857 (p≤0.0001).  
 
Table 3.  Estimated Fracture Risk in cases and controls as calculated by FRAX 
and QFracture 
 Fractures 
(n=246) 
Controls 
(n=338) 
p value 
QFracture Major Fracture 11.7 ± 7.0 7.9 ± 4.5 <0.0001 
FRAX Major Fracture 21.3 ± 8.2 10.8 ± 4.9 <0.0001 
QFracture Hip Fracture 4.0 ± 4.3 2.1 ± 2.0 <0.0001 
FRAX Hip Fracture 7.3 ± 6.4 2.8 ± 3.7 <0.0001 
Values are mean ± SD risk for major osteoporotic fracture and hip fracture as estimated by the FRAX 
and QFracture algorithms.  
 
 
 
Fig. 1 Correlation between FRAX and QFractureScores absolute risks for  
(A) Major Fracture and (B) Hip Fracture (n=584) 
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The FRAX algorithm can also produce absolute risks including a BMD measurement 
therefore these risks were also calculated in this dataset. Major fracture risk for the 
fracture cases was 18.7 ± 8.2 compared with 10.7 ± 5.3 for the control subjects 
(p<0.0001). Hip fracture risk for the cases was 5.3 ± 6.2 compared with 2.4 ± 3.4 for 
the control subjects (p<0.0001). Overall, when the risks calculated for FRAX 
(excluding BMD) were compared with FRAX (including BMD) (n=584) a significant 
difference was observed for estimated major fracture (p≤0.05) and hip fracture 
(p≤0.0001) risks. 
 
Table 4 Sensitivity, Specificity and AUC values for Prediction of 
Osteoporosis using QFracture and FRAX  
 
  Sensitivity Specificity AUC 
QFracture Major Fracture 16% 95% 0.668 
FRAX Major Fracture 37% 77% 0.665 
QFracture Hip Fracture 3% 99% 0.637 
FRAX Hip Fracture 7% 97% 0.710 
 
The values shown are derived from the whole study population of cases and controls.  
AUC – area under the curve, as determined by receiver-operator curve (ROC) analysis. 
 
Sensitivity and specificity for prediction of osteoporosis (as defined by femoral BMD) 
was calculated for QFracture and FRAX (excluding BMD). Both algorithms yielded 
high specificity but poor sensitivity (Table 4 and Figure 2) for prediction of 
osteoporosis as defined by DXA. 
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Fig. 2  ROC analysis for prediction of osteoporosis by FRAX and QFracture 
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Discussion 
 
The use of clinical risk factors to estimate 10-year probability of fracture is a 
significant advance in the management of osteoporosis. The aim of this study was to 
compare the performance of the FRAX and QFracture algorithms in a case-control 
study of postmenopausal women. In this study there was a significant difference in 
age (66 vs. 68y; p≤0.01), history of falls (69 vs. 158; p≤0.0001) and femoral T-score 
(-1.2 vs. -1.7; p≤0.0001) between the control and fracture groups respectively. This 
was not unexpected as these risk factors are among the strongest for fracture [19, 20], 
however, the history of falls data was striking. A history of falls was recorded in 39% 
of the total study sample. Fall history is included in the QFracture tool [18], but not in 
the FRAX tool. This might explain why QFractureScores had greater specificity for 
prediction of major fractures and hip fractures than the FRAX score, although this 
was counterbalanced by a poorer sensitivity. 
 
The absolute fracture risk values calculated in this study are broadly in agreement 
with previous published findings where QFracture predicted lower risks than FRAX 
[18, 21]. We think that the lower scores with the QFracture algorithm are likely to be 
due to the fact that this tool does not take previous fracture into account which is a 
strong risk factor for future fracture [22]. Reflecting this fact, the difference between 
estimates of fracture risk between FRAX and QFracture were much greater in the 
cases than in the controls (Table 3). It is not possible to determine from this cross-
sectional study however, whether fracture risk is underestimated by QFracture or 
overestimated by FRAX. Although the algorithms differed there were similarities 
between estimates with an overall correlation between FRAX and QFracture for 
major fracture of r=0.803 and for hip fracture of r=0.857 (p≤0.0001). Although both 
algorithms yielded high specificity for the detection of osteoporosis as defined by 
DXA, sensitivity was poor.  
 
At present there is no universally accepted policy for population screening in the UK 
to identify individuals with osteoporosis or those at high risk of fracture [23], which 
has been driven by the cost-benefit equation using the current diagnostic tools 
available. A potential advantage of QFracture is the collection of data on many more 
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risk factors than FRAX, but an important limitation is that it does not take previous 
fracture into account. Most of the variables assessed in the QFracture algorithm may 
have already been gathered in patients electronic GP record in the UK or could be 
collected by a clinician during a standard consultation [18]. The FRAX score is also 
easy and quick to calculate and can be used with or without the inclusion of a femoral 
neck BMD measurement [21]. Some studies have indicated that FRAX does not offer 
significant advantages over less complex models that also incorporate BMD [24, 25].  
Both FRAX and QFracture are platform technologies which theoretically could be 
upgraded as new validated risk indicators become available [26]. However these 
additional risk factors would need to be validated on the original populations. 
 
This study has some limitations including it’s retrospective nature, case-control 
design and relatively small sample size. However, to the best of the authors’ 
knowledge this is the first study to compare the FRAX and QFracture tools in an 
independent sample. 
 
There has been considerable debate as to how FRAX should be used in routine 
clinical practice. The procedure implemented on the UK National Osteoporosis 
Guideline Group website suggests that patients at high risk of fracture on the basis of 
FRAX should be treated without recourse to DXA, although this remains 
controversial since the vast majority of randomised controlled trials of osteoporosis 
therapies have focused on patients with osteoporosis as defined by DXA [27-29]. 
Until further evidence emerges to demonstrate that targeting patients for therapy on 
the basis of absolute fracture risk is effective it could be that the optimal use of FRAX 
and/or QFracture might be as a pre-screening tool to identify patients who should be 
referred for DXA. 
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